<DOC>
	<DOCNO>NCT00423748</DOCNO>
	<brief_summary>A phase 3 , randomize , double-blind , placebo-controlled study ass safety efficacy ambrisentan subject pulmonary arterial hypertension .</brief_summary>
	<brief_title>Study Assess Safety Efficacy Ambrisentan Subjects With Pulmonary Arterial Hypertension .</brief_title>
	<detailed_description>Subjects randomize study receive one two dos ambrisentan placebo . Inclusion base specify WHO functional classification . Rather , subject WHO Class I-IV symptom eligible 6-minute walk distance 150-450 meter meet study-specified hemodynamic criterion . Subjects anorexigen HIV infection relate PAH eligible subject congenital heart disease pediatric subject exclude . The study require historical cardiac catheterization diagnostic procedure .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<criteria>18 year age order Current diagnosis either PPH orPAH secondary scleroderma spectrum disease , systemic lupus erythematosus , anorexigen use , HIV infection Screening Visit Right heart catheterization , complete prior Screening Visit must meet prespecified hemodynamic criterion Female subject childbearing potential must negative serum pregnancy test must agree use reliable double barrier method contraception study completion least four week follow final study visit Male subject must inform potential risk testicular tubular atrophy infertility associate take study drug query regard understand potential risk describe Informed Consent Form PAH due associate congenital heart disease , coronary artery disease , leave heart disease , interstitial lung disease , chronic obstructive pulmonary disease , venoocclusive disease , chronic thrombotic and/or embolic disease , sleep apnea Portopulmonary hypertension Bosentan within four week prior Screening Phosphodiesterase type V inhibitor chronic prostanoid therapy within four week prior Screening IV inotrope use within two week prior Screening ALT AST lab value great 1.5 time upper limit normal Pulmonary function test meet prespecified criterion Contraindication treatment ERA History malignancy basal cell carcinoma skin situ carcinoma cervix within past five year Females pregnant breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
</DOC>